May 28, 2026 8:00 am EDT Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
May 12, 2026 8:00 am EDT Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Apr 22, 2026 8:00 am EDT Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Apr 6, 2026 8:00 am EDT Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Mar 26, 2026 8:00 am EDT Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Feb 24, 2026 8:00 am EST Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Feb 18, 2026 9:00 am EST Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Feb 11, 2026 7:00 am EST Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Feb 2, 2026 7:00 am EST Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Jan 27, 2026 8:00 am EST Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
